Medicare beneficiaries started to receive outpatient prescription drug benefits beginning in 2006, with the implementation of Medicare Part D. As a result, Medicare’s share of national prescription drug spending increased. Explain how the pharmaceutical companies would respond to this policy change in terms of their R&D activities. What is the economic term used to describe this phenomena?